Published: July 11, 2016

InvitroCue Commences Pancreatic Toxicity Assay Development

Logo

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modeling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. This builds on a previous MOU between InSphero and InvitroCue on the in vitro cell-based hepatotoxicity assay.

InvitroCue has a history of pioneering technology and establishing industry firsts for liver-related testing assays through its partnerships with leading pharmaceutical and biotech companies. As part of InvitroCue’s objective to cater for increasing demand for more innovative products and services it has also introduced disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis, malaria and perfused human liver tissue. The strategic partnership with InSphero demonstrates the company’s ongoing commitment to deliver customer-centric innovation and best-in-class technological solutions.

“We aim to offer a convenient assay solution for our biopharmaceutical customers to accelerate preclinical anti-diabetic drug development and assessment of potential pancreatic toxicities associated with their metabolites,” commented Dr. Steven Fang, Executive Director of InvitroCue.

InSphero CEO and co-founder Dr. Jan Lichtenberg said, “The collaboration allows InvitroCue to leverage our next-generation 3D InSight™ Islet Microtissues as part of their toxicity testing services and establishes important inroads as we continue to grow our business in the important Asia-Pacific Market.”

For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
mgregorowski@citadelmagnus.com

Other News

Dr. Madhu Nag appointed to SLAS board of directors from January 1, 2025
News

InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors

InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

Read More »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource